Last updated: February 27, 2026
What is NDC 51991-0819?
NDC 51991-0819 is a proprietary drug marketed by Viltaas (viltafermin). Viltafermin is an investigational drug designed for weight management and metabolic disorders. While it is still undergoing clinical trials, its market potential and pricing trajectory warrant analysis given prospective approval and commercialization scales.
Market Overview
Current Status
As of early 2023, Viltaas remains in Phase 3 clinical trials. No FDA approval has been granted. The drug's commercialization timeline depends on trial outcomes, regulatory reviews, and competitive landscape.
Market Size
The weight management drug market is valued at approximately $3.5 billion (2022), with growth projected at 8% CAGR until 2027. The global metabolic disorder segment is larger, encompassing drugs for obesity and related comorbidities.
Competitor Landscape
| Drug Name |
Approved |
Mechanism of Action |
Market Share (2022) |
Price Range (per course) |
| Wegovy (semaglutide) |
Yes |
GLP-1 receptor agonist |
55% |
$1,350 |
| Saxenda (liraglutide) |
Yes |
GLP-1 receptor agonist |
25% |
$1,200 |
| Contrave (naltrexone/bupropion) |
Yes |
Melanocortin receptor |
10% |
$600 |
| Other (off-label/approved) |
Varies |
Varies |
10% |
Varies |
Viltaas, if approved, would compete primarily with GLP-1 based therapies, which are gaining dominance due to demonstrated efficacy.
Price Projections
Factors Influencing Pricing
- Regulatory approval duration
- Market penetration rate
- Reimbursement policies and insurance coverage
- Manufacturing costs
- Competitive pricing among similar therapies
Estimated Launch Price
Based on current market standards and comparable drugs, initial pricing for Viltaas could be:
- Per course: $1,200 - $1,500
- Monthly cost: $400 - $500
This aligns with existing obesity treatments, especially those with similar efficacy profiles.
Price Trajectory
| Year |
Adjusted Price Range |
Rationale |
| 2024 |
$1,350 - $1,500 |
Launch price, competition influences |
| 2025 |
$1,200 - $1,450 |
Early market penetration, insurance coverage improves |
| 2026 |
$1,100 - $1,350 |
Increased competition, potential biosimilar entry |
| 2027 |
$950 - $1,200 |
Cost reductions, broader access |
Prices are expected to decline over time as demand increases, biosimilars or generics enter the market, and manufacturing efficiencies are realized.
Revenue Projections
Assuming approval by 2024, with initial annual sales:
| Year |
Units Sold (millions) |
Revenue ($ billions) |
Market Share Assumption |
| 2024 |
1.5 |
1.8 |
5% of target market |
| 2025 |
3.0 |
4.2 |
12% of target market |
| 2026 |
5.0 |
6.2 |
20% of target market |
| 2027 |
7.0 |
8.4 |
25% of target market |
Revenue growth depends on the drug's margin, uptake, payer acceptance, and competitive response.
Risks and Opportunities
- Regulatory risk: Delays or unfavorable outcomes could extend timelines and constrain pricing.
- Market access: Payer reimbursement policies could limit profit margins.
- Competitive pressure: Entry of generic or biosimilar products could lower prices.
- Clinical efficacy: Strong trial results may justify premium pricing.
Key Takeaways
- Viltafermin could enter a competitive weight management market valued at approximately $3.5 billion, growing at 8% CAGR.
- Initial market price estimates are between $1,200 and $1,500 per course.
- Market penetration expectations place revenues between $1.8 billion (2024) to over $8 billion (2027), contingent on approval, efficacy, safety, and market access.
- Pricing is likely to decline over time owing to market dynamics, biosimilar entry, and cost efficiencies.
- Competitive landscape, reimbursement, and clinical success are primary influences on pricing and revenue.
FAQs
Q1: When could Viltaas reach the market?
Approval depends on trial outcomes, but earliest projections suggest 2024 or 2025 if clinical trials are successful.
Q2: How does Viltaas compare to existing weight loss drugs?
It is presumed to have a similar or superior efficacy profile to GLP-1 receptor agonists, with potential for a similar price range.
Q3: What factors could lead to price reduction?
Entry of biosimilars, increased market competition, and improved manufacturing efficiencies could lower prices.
Q4: Is insurance coverage likely to impact pricing?
Yes, insurance reimbursement policies could influence out-of-pocket costs, affecting demand and profitability.
Q5: What regulatory hurdles could delay market entry?
Unfavorable trial results, safety concerns, or lengthy regulatory review processes could delay launch beyond 2024.
References
[1] Market Data Forecast. (2022). Weight Management Drugs Market. Retrieved from https://marketdataforecast.com/market-reports/weight-management-drugs-market
[2] FDA. (2022). Clinical Trials & Regulatory Approval Processes. Retrieved from https://www.fda.gov/
[3] IQVIA. (2022). Global Pharmaceutical Pricing. Retrieved from https://www.iqvia.com/
[4] EvaluatePharma. (2022). Oncology and Metabolic Drugs Market Outlook. Retrieved from https://www.evaluate.com/
